Neurocrine Biosciences (NBIX) Payables (2016 - 2021)
Historic Payables for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $205.9 million.
- Neurocrine Biosciences' Payables rose 2076.25% to $205.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $205.9 million, marking a year-over-year increase of 2076.25%. This contributed to the annual value of $168.7 million for FY2020, which is 1939.14% up from last year.
- Per Neurocrine Biosciences' latest filing, its Payables stood at $205.9 million for Q3 2021, which was up 2076.25% from $190.9 million recorded in Q2 2021.
- Neurocrine Biosciences' Payables' 5-year high stood at $205.9 million during Q3 2021, with a 5-year trough of $852000.0 in Q1 2017.
- Its 5-year average for Payables is $103.2 million, with a median of $95.0 million in 2019.
- As far as peak fluctuations go, Neurocrine Biosciences' Payables plummeted by 5984.92% in 2017, and later skyrocketed by 525798.12% in 2018.
- Quarter analysis of 5 years shows Neurocrine Biosciences' Payables stood at $53.5 million in 2017, then skyrocketed by 61.39% to $86.4 million in 2018, then surged by 63.59% to $141.3 million in 2019, then grew by 19.39% to $168.7 million in 2020, then grew by 22.05% to $205.9 million in 2021.
- Its Payables was $205.9 million in Q3 2021, compared to $190.9 million in Q2 2021 and $171.9 million in Q1 2021.